Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
14 hedge funds and large institutions have $21.6M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
182% more capital invested
Capital invested by funds: $7.67M → $21.6M (+$14M)
13% less funds holding
Funds holding: 16 → 14 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$365K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$300K |
| 3 |
Morgan Stanley
New York
|
+$171K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$41.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$336K |
| 2 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
-$77K |
| 3 |
VF
Virtu Financial
New York
|
-$52K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$40K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$39K |
VRPX Hedge Fund Activity: Q1 2022 in Review
14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q1 2022, worth a combined $21.6M — up 182% from $7.67M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VRPX and 5 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $365K. The largest seller was Citadel Advisors, exiting entirely with an estimated $336K sold.
- 14 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q1 2022, down from 16 in Q4 2021.
- Funds reported $21.6M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q1 2022, up 182% quarter-over-quarter.
- 5 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of -2 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $365K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $336K sold.
Based on aggregated 13F filings for Q1 2022.